-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck KGaA agrees to buy Bio-Techne for USD 73 a share in USD 11.3 billion deal

PUBT·06/25/2026 10:11:00
Listen to the news
Merck KGaA agrees to buy Bio-Techne for USD 73 a share in USD 11.3 billion deal
  • Merck KGaA agreed to buy Bio-Techne for USD 73 per share in cash, valuing the deal at about USD 11.3 billion.
  • Offer implies a 36% premium to the one-month volume-weighted average share price.
  • Closing targeted for late 2026 or early 2027, subject to shareholder and regulatory clearances.
  • Merck expects about EUR 140 million of annual cost synergies, fully realized by year 3 post-close.
  • Merck plans to fund the purchase with cash on hand and new debt, aiming to keep an investment-grade credit rating.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606250610PR_NEWS_USPR_____CG92233) on June 25, 2026, and is solely responsible for the information contained therein.